Standard Life Aberdeen announces Cecilia Reyes to its Board as Non-Executive Director

– UK, Edinburgh –  Standard Life Aberdeen Plc (LON: SLA) today announced that Cecilia Reyes will be appointed as a Non-Executive Director with effect from 1 October 2019.

Cecilia brings 28 years of experience operating in international financial markets in leadership positions in investment and risk management. Latterly, she was Group Chief Risk Officer of Zurich Insurance Group responsible for the global function comprising Group Risk Management and the Enterprise Risk Management Framework. Prior to that, she was their Group Chief Investment Officer, responsible for the execution of the investment management value chain, including analysis, development and global implementation of the investment strategy for the Group’s investments. In both positions, she was member of the group’s Executive Committee.

Commenting on her appointment, Sir Douglas Flint, Chairman of SLA, said: “I am very pleased to welcome Cecilia to our Board. Her direct experience of risk management and in-depth knowledge of the investment process will be of great value to our discussions at both the Board and the Risk and Capital Committee”.

On joining the Board, Cecilia will be appointed a member of the Risk and Capital Committee and of the Remuneration Committee.

Following this appointment, the Board will comprise four executive directors, seven non-executive directors and the Chairman. The Board will be made up of five women and seven men. The Financial Conduct Authority and the Prudential Regulation Authority have been notified of this appointment.

For more information: https://www.standardlifeaberdeen.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.